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200 Inﬂammatory cytokines and markers of bone metabolism during
CF infective exacerbations
E.F. Shead1, C.S. Haworth2, E. Gunn2, H.C. Barker2, D. Bilton2, M.A. Scott1,
J.E. Compston3. 1Department of Haematology, Addenbrooke’s Hospital,
Cambridge, United Kingdom; 2Adult CF Centre, Papworth Hospital, Cambridge,
United Kingdom; 3Department of Medicine, University of Cambridge, Cambridge,
United Kingdom
Rationale: CF adults are at increased risk of osteoporosis. The mean concentration
of IL-6 is an independent predictor of change in bone mineral content, suggesting
that pulmonary infection may inﬂuence bone metabolism in adults with CF.
Objective: The aim of this study was to investigate the variation in levels of
inﬂammatory cytokines and bone metabolism markers before, during, and after
intravenous antibiotic treatment of infective exacerbations in patients with CF.
Methods: Blood samples were collected at baseline when clinically stable, at day 1
of IV antibiotic therapy, at day 14 (end of IVs) and day 42 (follow-up). Serum
osteocalcin and NTX were measured using commercially available ELISAs, in
addition to IL-1b, IL-6, TNFa, receptor activator for nuclear factor kB ligand
(RANKL), TGFb and osteoprotegerin (OPG).
Results: During an exacerbation signiﬁcant variations in serum levels of NTx
(p = 0.027), RANKL (p = 0.05), OPG (p = 0.03), IL-6 (p = 0.005) and TNFa
(p = 0.003) were seen. A signiﬁcant increase in NTx was seen at day 1 and day 14
of exacerbation (p< 0.05) compared to baseline. Baseline osteocalcin levels in CF
patients were signiﬁcantly lower than those in the normal controls (p< 0.05). An
increase in RANKL (p< 0.05) and OPG (p< 0.05) was seen at day 14, decreasing
the RANKL:OPG ratio.
Conclusion: The results demonstrate increased levels of proinﬂammatory cytokines
during CF infective exacerbations. The increase in NTx at day 1 and the decrease
RANKL:OPG ratio at day 14 indicates that osteoclast activity is increased at the
start of exacerbations and reduces after IV antibiotic therapy.
201 The effect of vitamin D and calcium supplementation in children
and adolescents with cystic ﬁbrosis and low bone mineral
density
E. Hatziagorou1, E. Kazantzidou2, F. Kirvasilis1, P. Savopoulou1, J. Tsanakas1.
1Third Dept of Pediatrics, Pediatric Pulmonology Unit, Aristotle University,
Hippokration Hospital, Thessaloniki, Greece; 2Second Dept of Radiology,
Hippokration Hospital, Thessaloniki, Greece
Background: Low bone mineral density (BMD) is a relatively frequent ﬁnding
among patients with Cystic Fibrosis (CF). Low BMD might be related to vitamin D
and calcium malabsorption, although the pathogenesis of low BMD in CF is multi-
factorial.
Aim: To assess the prevalence of low BMD among children and adolescents with
CF and to evaluate the effect of vitamin D and calcium supplementation.
Methods: BMD was measured in the lumbar spine of 35 children and adolescents
with CF (17 males, aged 15.2 ±4.1 years), using dual energy x-ray absorptiometry
(DEXA). Lung function (FVC, FEV1), body mass index (BMI), calcium urinary
secretion and serum calcium alkaline phosphatase were measured. Calcium and
vitamin D supplementation were adjusted according to BMD z-scores. The effect
of the treatment was evaluated after 18 months.
Results: Six of the 35 patients (17%) had osteoporosis and 10 of the 35 (29%)
patients had osteopenia. The BMD z scores were improved signiﬁcantly 18 months
after calcium and vitamin D supplementation (p = 0.013) (BMD z scores: −2.33±0.6
and −1.46±0.9, respectively). One of the 16 patients (6%) developed nephrolithiasis
and increased calcium urinary secretion 10 months after calcium supplementation.
Conclusions: Osteopenia and osteoporosis are common ﬁndings in CF patients.
Early detection of low BMD and consequent vitamin D and calcium intervention
may improve BMD.
202 Bone health status in children with cystic ﬁbrosis
T. Kapustina1,2, V. Fedorova1, S. Semikin1, N. Kapranov2. 1Russian State Medical
University, Moscow, Russian Federation; 2Research Centre for Medical Genetics,
Moscow, Russian Federation
CF patients as has been shown in several researches have low absorption of calcium
and vitamin D. However adequate intake calcium and vitamin D in prepuberty
and puberty is important for achievement of peak bone mass and reduces risk of
osteoporosis.
Aim: To reveal inﬂuence of calcium and vitamin D supplementation on bone
mineral density in CF children.
Methods: 109 CF children (50M and 59F, 5.1−18 years, FEV1% 73.97%±23.5)
were studied. 38 (35%) children have “moderate” and 71 (65%) “severe” pheno-
type. 12 (11%) children used inhaled steroids, 21 (19.3%) received oral steroids
(0.5mg/kg every other day more than 1 year). Mineral bone density (BMC, g and
BMD, g/cm2) in the lumbar spine (L2-L4) was measured using osteodensitometry
“DPX-MD+”, Lunar. All patients were pancreatic insufﬁciency, received adequate
basic therapy including multivitamins.
Results: Low mineral bone density was found in 52.3% (osteoporosis in
24.8% cases, meanZ-score-3.58, S.D. 0.92). 23 children from the surveyed group
(12M and 11F, 9.3−16.9 years, Z-score-3.27, S.D. 0.96) received supplementation of
calcium (1000mg/day) and colecalciferol (400 IU/day) for 12 months. 15 patients
(7F and 8M, 9.4−17.5, Z-score-1.32, S.D. 0.35) on adequate basic therapy including
multivitamins, but not receiving calcium and vitamin D supplementation, were
included into control group. After control osteodensitometry we revealed increase of
bone mineral density: before treatment 0.74±0.1, after treatment 0.860±0.11 g/cm2
(P< 0.007) in group of the patients receiving calcium and vitamin D supplementa-
tion. In control group increase bone mineral density was not statistically signiﬁcant
(from 0.66±0.11 to 0.700±0.11 g/cm2).
Conclusion: Calcium and vitamin D supplementation have positive effect on
mineral bone density in children with CF.
203 Three day continuous subcutaneous glucose monitoring (CSGM)
in the clinical management of adult patients with CF and
diabetes (CFRD)
H. Watson, H. Barker, S. Henman, A. Lyon, C.S. Haworth, D. Bilton. Adult Cystic
Fibrosis Centre, Papworth Hospital, Cambridge, United Kingdom
Introduction: Numerous studies demonstrate the association between CFRD, dete-
riorating nutritional status and pulmonary health. CSGM is increasingly being used
in the management of type 1 diabetes for adjusting insulin therapy with the aim of
achieving better glycaemic control.
Aim: To assess the utility of CSGM in adults with CFRD in determining
a. The adequacy of current insulin therapy
b. The need to commence insulin therapy.
Methods: CSGM was performed in patients with abnormal OGTT or raised random
glucose or patients with known diabetes and deteriorating weight and/or clinical
status.
Results: Of the 17 patients studied, 8 had abnormal OGTT, 2 had a raised random
glucose. Following abnormal CSGM six patients (35%) commenced insulin therapy.
Four patients (23%) showed no raised sugars on CSGM, therefore no treatment was
started.
Seven patients had known diabetes; six patients (35%) with previously normal
HbA1c and BM monitoring had raised sugars on CSGM which necessitated a
change in dose or type of insulin therapy. In one patient (6%) sugars were normal
on CSGM and hence no change in treatment was necessary.
Conclusion: Three day CSGM identiﬁes excursions in blood glucose which would
not have been detected by conventional means and supports useful therapeutic
intervention.
